Becton Dickinson and Co vs Jabil Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Jabil Inc trades at $359.61 (market cap $35.27B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | JBL | |
|---|---|---|
Market Cap | $48.93B | $35.27B |
Sector | Health | Technology |
52-Week High | $185.39 | $385.50 |
52-Week Low | $138.62 | $192.49 |
Enterprise Value | $65.03B | $37.81B |
Dividend Yield | 2.34% | 0.1% |
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Jabil trades at $341.22, down 1.0% today but maintains strong momentum with a bullish technical outlook and consistent earnings beats. The stock shows robust fundamentals with revenue growth from $29.8B in 2025 to $33.6B projected for 2026, supported by AI infrastructure demand and diversified operations. Recent news highlights Jabil's 31.6% six-month surge and strategic expansion with a new logistics hub in Penang.
Jabil presents a compelling growth story driven by AI and manufacturing excellence, with analyst consensus pointing to significant upside (target $448.29). However, elevated valuation multiples (P/E 42.13) and competitive pressures in the EMS sector warrant caution. The stock's technical strength and fundamental momentum support a positive outlook, though investors should monitor execution risks and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →